Evidence map›Paper›PMID 34959525›Full record

ArticlePathogens (Basel, Switzerland)2021

From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice.

David Petroff, Olaf Bätz, Katrin Jedrysiak, Anja Lüllau, Jan Kramer, Hjördis Möller, Renate Heyne, Burkhard Jäger, Thomas Berg, Johannes Wiegand

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Beyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. [The status of national and global hepatitis C elimination].Innere Medizin (Heidelberg, Germany) · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

David PetroffClinical Trial Centre, University of Leipzig, 04107 Leipzig, Germany.ORCID 0000-0002-6916-1465
Olaf BätzLADR Laboratory Group Dr. Kramer & Colleagues, 21502 Geesthacht, Germany.
Katrin JedrysiakLADR Laboratory Group Dr. Kramer & Colleagues, 21502 Geesthacht, Germany.
Anja LüllauLADR Laboratory Group Dr. Kramer & Colleagues, 21502 Geesthacht, Germany.
Jan KramerLADR Laboratory Group Dr. Kramer & Colleagues, 21502 Geesthacht, Germany.
Hjördis MöllerLeberzentrum am Checkpoint, 10961 Berlin, Germany.
Renate HeyneLeberzentrum am Checkpoint, 10961 Berlin, Germany.
Burkhard JägerLeberzentrum am Checkpoint, 10961 Berlin, Germany.
Thomas BergDivision of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany.
Johannes WiegandDivision of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany.ORCID 0000-0001-9233-4064
Leipzig University · DE

Funding

Gilead Sciences (United States) IN-DE-342-4479
6 · The paper itself

Abstract

(1) Background: Low rates of hepatitis C virus (HCV) diagnosis and sub-optimal linkage to care constitute barriers toward eliminating the infection. In 2012/2013, we showed that HCV screening in primary care detects unknown cases. However, hepatitis C patients may not receive further diagnostics and therapy because they drop out during the referral pathway to secondary care. Thus, we used an existing network of primary care physicians and a practice of gastroenterology to investigate the pathway from screening to therapy. (2) Methods: HCV screening was prospectively included in a routine check-up of primary care physicians who cooperated regularly with a private gastroenterology practice. Anti-HCV-positive patients were referred for further specialized diagnostics and treatment if indicated. (3) Results: Seventeen primary care practices screened 1875 patients. Twelve individuals were anti-HCV-positive (0.6%), six of them reported previous antiviral HCV therapy, and one untreated patient was HCV-RNA-positive (0.05% of the population). None of the 12 anti-HCV-positive cases showed up at the private gastroenterology practice. Further clinical details of the pathway from screening to therapy could not be analyzed. (4) Conclusions: The linkage between primary and secondary care appears to be problematic in the HCV setting even among cooperating partners, but robust conclusions require larger datasets.

Indexed as

eliminationHCV-RNAhepatitis CWorld Health Organization

Identifiers

PMID34959525
PMCPMC8706228
OpenAlexW3216544237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.